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Objective: This paper was undertaken to review the experience at our
institution with bilateral sequential lung transplantation for cystic fibrosis.
Methods: Since 1989, 103 bilateral sequential lung transplants for cystic
fibrosis have been performed (46 pediatric, 48 adult, 9 redo); the mean age
was 21 6 10 years. Cardiopulmonary bypass was used in all but one
pediatric (age <18) transplant, and in 15% of adults. Results: Hospital
mortality was 4.9%, with 80% of early deaths related to infection. Bronchial
anastomotic complications occurred with equal frequency in the pediatric
and the adult populations (7.3%). One- and 3-year actuarial survival are
84% and 61%, respectively (no significant difference between pediatric and
adult age groups; average follow-up 2.1 6 1.6 years). Mean forced expira-
tory volume in 1 second increased from 25% 6 9% before transplantation
to 79% 6 35% 1 year after transplantation. Acute rejection occurred 1.7
times per patient-year, with most episodes taking place within the first 6
months after transplantation. The need for treatment of lower respiratory
tract infections occurred 1.2 times per patient in the first year after
transplantation. Actuarial freedom from bronchiolitis obliterans was 63%
at 2 years and 43% at 3 years. Redo transplantation was performed only in
the pediatric population and was associated with an early mortality of 33%.
Eight living donor transplants (four primary transplants, four redo trans-
plants) were performed with an early survival of 87.5%. Conclusion: Patients
with end-stage cystic fibrosis can undergo bilateral lung transplantation
with morbidity and mortality comparable to that seen in pulmonary
transplantation for other disease entities. (J Thorac Cardiovasc Surg 1998;
115:404-14)
Cystic fibrosis (CF) is a genetic disorder affecting 1in every 3000 live births in the United States, and
3.3% of all Americans are asymptomatic carriers of
the CF gene.1 It is the most common lethal genetic
disease in Caucasians, with 95% of all deaths caused
by respiratory failure related to bronchiectasis. In-
tense research into the pathophysiology of this
disease combined with aggressive medical therapies
have extended the median survival from l0 years of
age in the 1960s to 30 years of age in the 1990s;
however, 25% of patients still die before the age of
20.2 Despite the fact that a better understanding of
the genetic basis for the disease exists, no cure has
been found and 300 to 400 patients with CF still die
from respiratory failure in the United States alone
each year.
Although it would seem counterintuitive to per-
form transplantation (with its obligatory need for
immunosuppression) in a chronically infected pa-
tient, this is the only therapy available at present for
those CF patients with end-stage lung disease.
Heart-lung transplantation was first performed on a
patient with CF in 1983 and isolated bilateral lung
transplantation in 1987.3 Heart-lung transplantation
was the preferred method of transplantation for
these patients in the 1980s. At present, except in
those few centers still favoring combined heart-lung
transplantation, isolated bilateral sequential lung
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transplantation is now the procedure of choice.
According to the January, 1997, report of the St.
Louis International Lung Transplant Registry, 932
transplants have been performed for this disease
worldwide.4 We reviewed the lung transplantation
experience for CF at the Washington University
School of Medicine with the aim of evaluating
survival, rejection incidence, complications of the
procedure, infection risk after transplantation, and
rate of development of obliterative bronchiolitis
(OB). This experience covers a period from 1989 to
the present and includes all ages, both adult and
pediatric.
Methods
Patient selection. Since November 1989, 116 bilateral
sequential lung transplants have been performed at our
combined adult (Barnes-Jewish Hospital) and pediatric
(St. Louis Children’s Hospital) hospitals for patients with
CF. The pediatric population at our institution is defined
as those less than 18 years old at the time of transplanta-
tion. This study focuses on the 103 (55 pediatric, 48 adult)
bilateral sequential lung transplantations performed in 94
patients as of September of 1996. The remaining have
insufficient follow-up to be included. This group repre-
sents 23% of the total transplantations performed at this
institution over the same time period. Nine patients, all in
the pediatric population, have undergone retransplanta-
tion. Additionally, the pediatric group contains eight
patients who have undergone living donor transplants,
four as a primary transplantation procedure and four as
retransplantation procedures. Mean age at transplanta-
tion for the entire population was 21 6 10 years (13 6 3
years in the pediatric population and 29 6 8 years in the
adult group) and mean weight was 43 6 15 kg (32 6 10 kg
in the pediatric and 52 6 12 kg in the adult group).
As with most centers, we have used the parameters
outlined by Kerem and associates5 that predict a 50%
2-year mortality as guidelines for initial referral for trans-
plantation (Table I). Despite these general guidelines, it is
clear that people with CF, especially children, are prone to
have a somewhat unpredictable decline in pulmonary
function, making their clinical course and appropriate
window for transplantation somewhat difficult to forecast.
This is supported by data showing a mortality rate as high
as 40% to 60% among patients with CF on transplant
waiting lists in the United States and the United King-
dom.6 Other factors that may serve as relative indicators
in deciding to proceed toward transplantation include
need for continuous supplemental oxygen, increased fre-
quency of hospitalizations to receive parenteral antibiot-
ics, progressive weight loss, and unacceptably poor quality
of life. Contraindications to transplantation are listed in
Table II.
Once the decision has been made to consider transplan-
tation, a thorough pulmonary and general transplant
evaluation is initiated. Among other studies, this includes
pulmonary function testing, a 6-minute walk test, room air
blood gas, establishing the patient’s microbiologic profile
by sputum culture or bronchoalveolar lavage (BAL) (in-
cludes use of standard selective media to enhance recov-
ery of Burkholderia cepacia and other unusual gram-
negative organisms), examination of the family’s
psychosocial and financial resources, education of the
patient and family regarding transplantation, cardiologic
evaluation (echocardiogram, radionuclide ventriculogra-
phy, and cardiac catheterization in adults), and initiation
of an aggressive pretransplantation rehabilitation pro-
gram. Evaluation of sinus disease by coronal computed
tomographic scan of the head is performed, but surgical
therapy is undertaken only for significant symptoms or
severe polyp disease. Close communication with referring
physicians is vital in instituting and maintaining a regimen
of appropriate antibiotics, aggressive feeding (including
nighttime gastrostomy feeding supplements), exercise,
and chest physiotherapy—all with the aim of maximizing
pulmonary function and overall physical condition before
transplantation. Once the patient has been listed long
enough that we expect the transplant to take place within
3 months, we then ask him or her to relocate to St. Louis.
This allows for regular medical checkups to more closely
monitor the patient’s condition and maximize the fre-
quently tenuous physiologic and psychologic state as the
time of transplantation approaches. Additionally, it per-
mits the family an opportunity to establish a support
network within our local transplant community.
The transplant procedure. The method of standard
donor lung harvest has been previously described.7 The
lungs are perfused with alprostadil (prostaglandin E1),
flushed with modified Euro-Collins solution, excised en
bloc, and transported on ice to the recipient’s surgical
suite. Recipients receive perioperative antibiotics appro-
priate for their specific microbiologic profile. The trans-
plantation itself is performed through a bilateral thora-
costernotomy incision, which provides ready access to
both hilar regions and also allows improved exposure for
Table I. Factors associated with a high risk of
mortality in ,2 years
Factors Risk
FEV1 ,30% predicted for women and children
FEV1 ,20% predicted for adult males
PaO2 ,55 mm Hg
PaCO2 .50 mm Hg
Table II. Contraindications to lung transplant
Absolute Relative
HIV Highly resistant bacterial colonization
(B. cepacia, S. maltiphalia)
Malignancy Renal failure
Hepatitis B (active) Hepatic failure
Mycobacterium
tuberculosis (active)
Left ventricular dysfunction
Irreversible central
nervous system
injury
Diabetes mellitus with vasculopathy
Osteoporosis
Medical noncompliance issues
Familial dysfunction
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taking down chest wall adhesions, which may be extensive
and severe in patients with CF who have frequently had
previous interventions.8 Prior surgery has not been used
as a contraindication to transplantation, and 29 of 103
(28%) of our patients have had either previous surgery,
thoracostomy tube, or pleurodesis for recurrent pneumo-
thorax.
Although the bilateral sequential technique of trans-
plantation has obviated the need for cardiopulmonary
bypass (CPB) in 85% of our adult population, it has been
used in all but one transplant in the pediatric population.
CPB is used routinely in children because the smaller
airways make single lung ventilation with either a double-
lumen endobronchial tube or bronchial blockers very
difficult, particularly in the setting of CF where tenacious
secretions are difficult to clear. These patients may have
very poor tolerance of any manipulation because of the
frequently heavy bacterial burden contained within the
severely bronchiectatic lungs. Use of CPB allows for
simultaneous pneumonectomy in the recipient and thus
provides a window of opportunity before implantation of
the new lungs during which the anesthetist can perform a
thorough lavage of the colonized trachea and blind main-
stem bronchial stumps with tobramycin solution. Imple-
mentation of CPB can potentially minimize donor lung
ischemic time by allowing for rapid dissection of hilar
structures without compromising stability of the recipient.
Patients are weaned from CPB once both lungs are
implanted, and aprotinin has been used routinely in an
attempt to reduce the amount of postoperative bleeding in
this relatively high-risk patient population.9 Since 1993, in
the absence of systemic hypotension, all patients are
treated with a continuous infusion of alprostadil beginning
at the time of reperfusion and continuing for 48 hours
after the operation.
Postoperative management. Weaning from mechanical
ventilation has been achieved as rapidly as possible after
transplantation. Lung perfusion scans and bronchoscopy
are performed within the first 24 hours after the trans-
plantation to assess adequacy of revascularization, muco-
sal viability, and bronchial anastomotic appearance. Ag-
gressive nutritional support and physiotherapy initiated in
the preoperative interval are reinstituted early postoper-
atively and ambulation is encouraged as soon as possible.
Routine hematologic, biochemical, and drug level analy-
ses are performed and adjustments in medications are
made accordingly. Surveillance bronchoscopy for rejec-
tion (assessed by transbronchial biopsy) and lower respi-
ratory infections (assessed by BAL) is performed rou-
tinely at 1 to 2 weeks, 1 month, 2 months, 3 months, 6
months, and 12 months postoperatively and also when
clinically indicated by chest x-ray examination, fever, or
increasing oxygen requirements. Additionally, graft func-
tion and overall patient rehabilitation and functional
status are assessed by pulmonary function testing and
6-minute walk. On discharge from the hospital, each
patient is provided with a home spirometer (Puritan-
Bennet model PB110, Wilmington, Mass.) and asked to
perform spirometry twice daily. A drop in forced expira-
tory volume in 1 second (FEV1) of greater than 10% from
baseline is considered an indication for contacting our
transplant service for possible intervention.
Immunosuppressive and antimicrobial regimens. Im-
munosuppression consists of cylosporine (INN: ciclo-
sporin), azathioprine, and prednisone. Azathioprine is
given immediately before going to the operating room in
a dose of 2.5 to 3.0 mg/kg intravenously and is continued
at this same level as a single daily dose postoperatively.
Cyclosporine (CSA) is begun as a continuous intravenous
infusion immediately after the operation and, along with
azathioprine and steroids, is converted to oral dosing once
the patient is extubated and tolerating enteral feeding.
Our target CSA trough level is 300 to 350 ng/ml in the
early postoperative period until approximately 1 year after
transplantation and 250 to 300 ng/ml thereafter if no
evidence of ongoing rejection exists. Extreme variability
exists between individuals in dose range because gastro-
intestinal absorption and the rate of hepatic clearance
vary greatly within this patient population. Systemic cor-
ticosteroids are similarly begun in the immediate postop-
erative period with methylprednisolone at 0.5 mg/kg per
day intravenously. After conversion to oral prednisone,
the dose is left at 0.5 mg/kg per day for the first 3 to 6
months after transplantation and is then gradually tapered
to 0.1 to 0.2 mg/kg per day by 12 months. Acute rejection
episodes, as documented by transbronchial biopsy, are
treated with intravenous methylprednisolone in a dose of
10 mg/kg per day for 3 days in the pediatric population
and 0.5 to 1 gm intravenously for 3 days in the adult
population. Second- and third-line forms of therapy for
refractory rejection include antithymocyte gamma-globu-
lin (ATGAM, The Upjohn Company, Kalamazoo, Mich.),
methotrexate, and OKT3.
Intraoperative and postoperative antimicrobials are
chosen on the basis of preoperative sputum culture iso-
lates and generally include intravenous tobramycin and a
b-lactam or fluoroquinolone. Intravenous antibiotics are
typically administered for 7 to 10 days postoperatively and
drug levels are followed closely because at least a mild
degree of renal insufficiency frequently occurs early after
surgery. Inhaled tobramycin and colistin are added after
the course of intravenous antibiotics in most patients.
Patients with early and late postoperative lower respira-
tory infections are treated with appropriate oral, inhaled,
and intravenous antibiotics as an outpatient as often as
possible. In the pediatric population, if either the recipient
or donor are cytomegalovirus (CMV) IgG positive at the
time of transplantation, prophylactic intravenous ganci-
clovir is given for 6 weeks, whereas in the adult patients 2
to 3 weeks of intravenous ganciclovir is administered only
in cases where the donor is CMV IgG positive and the
recipient is CMV IgG negative. Indications for treatment
of CMV infections occurring after the postoperative pro-
phylactic course of ganciclovir have been based on the
clinical picture in combination with a positive shell vial
assay on BAL culture and positive immunohistochemical
staining on transbronchial biopsy specimen. Viremia, as
documented by a positive blood buffy coat culture, in the
absence of symptoms is not considered an indication for
treatment. Prophylaxis against Pneumocystis carinii con-
sists of trimethoprim-sulfamethoxazole given once daily
until discharge at which time the regimen is changed to
three times per week. Although some degree of fungal
colonization of the airway is quite frequent preopera-
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tively, it is generally not treated aggressively unless colony
counts are heavy. Presence of fungus on postoperative
sputum cultures is treated by a variety of approaches on
the basis of the organism and colony count on culture. In
general, the patient may be treated with oral itraconazole
and aerosolized amphotericin B for 2 to 3 weeks, or they
may first receive a 5- to 10-day course of intravenous
amphotericin followed by 1 to 2 weeks of aerosolized
amphotericin B. Need for further therapy depends on the
results of follow-up cultures, which are performed rou-
tinely.
Statistics. Results are expressed as median with range
except where otherwise indicated. Actuarial freedom from
OB and death was calculated according to Kaplan-Meier
method and levels of significance with respect to survival
differences between groups were calculated using Mantel-
Haenszel method. Other comparisons were made using
Student’s t test and x2 analysis when indicated.
Results
Characteristics of the study population at large
are summarized in Table III. In addition to waiting
time and blood type, donors and recipients are
matched primarily on the basis of height. Median
waiting periods from the time of listing to the time
of transplantation were 267 days (range 3 to 989
days) for the entire group and 192 days (range 3 to
989) and 337 (range 40 to 969) days in the pediatric
and adult populations, respectively (p 5 0.03). Pre-
vious surgery (e.g., lobectomy) or pleurodesis with
thoracostomy tube drainage had been performed in
18 of the 55 pediatric transplant recipients (32.7%)
and in 11 of 48 adults (22.9%). Mechanical ventila-
tory support at the time of transplantation as used
for 17.5% of the recipients.
Donor lung ischemic times were shorter for the
pediatric lung recipients. Median times for the first
lung implanted were 271 minutes (range 188 to 382
minutes) and 300 minutes (range 146 to 412 min-
utes) (p 5 0.07), whereas those for the second lung
implanted were 318 minutes (range 244 to 425
minutes) and 421 minutes (range 207 to 633 min-
utes) (p 5 0.0001) in the pediatric and adult groups,
respectively. Adequate size match between donor
and recipient was obtained such that only one adult
required lobectomy of a donor lung to perform the
transplantation. Similarly, in the pediatric popula-
tion only one patient other than the eight who
underwent living donor transplantations required
lobar transplantation because of size mismatch with
the donor.
Average length of follow-up for the entire popu-
lation is 2.1 6 1.6 years. One- and 3-year actuarial
survivals are 84% and 61%, respectively. Breaking
this down into groups, the 1- and 3-year survival for
adults are 79% and 56%, whereas survival at the
same intervals in the pediatric age group are 90%
and 73%, respectively. The latter of these two, that
is, 3-year survival, approaches statistical significance
(p 5 0.056) when comparing the pediatric to the
adult population. Early mortality, defined as death
within 30 days of surgery or at any time during the
same hospitalization as the operation, occurred in 5
of 103 transplantations (4.9%). There were two
early deaths in the adult population. One of these
was due to respiratory failure related to early graft
dysfunction and superimposed viral pneumonia.
The second occurred in the only adult patient with
Burkholderia cepacia who underwent transplanta-
tion. This patient’s death 10 days after his transplan-
tation was due to B. cepacia pneumonia and bacte-
remia in conjunction with bilateral bronchial
dehiscence. In the pediatric population, no deaths
occurred after primary transplantation procedures,
and all three early deaths occurred in the group of
nine patients who underwent redo transplantations.
Two of these three patients had their redo trans-
plantation performed during the same hospitaliza-
tion as their primary transplantation (one 3 weeks
and the other 3 months after the primary transplan-
tation). Although generally multifactorial in nature,
the primary cause of death in the three pediatric
patients were pulmonary emboli with bacteremia,
invasive aspergillosis, and chronic respiratory failure
caused by graft failure, respectively.
The group of nine patients that underwent redo
transplantation did so for primary graft dysfunction
on three occasions and OB in the other six. Retrans-
plantation took place at a median of 395 days (range
20 to 778 days) after the initial transplantation. Four
of these nine patients had living donors for their
secondary transplantation. Posttransplantation lym-
phoproliferative disease (PTLD) occurred only once
in the adult population (2.1%) and in eight of 46
(17.4 %) of the pediatric patients. Three patients
with PTLD died as a complication of this disease.
PTLD was generally managed by tapering immuno-
suppression, and five patients treated as such subse-
Table III. Recipient/donor characteristics
Recipient age (yr) 20.6 6 9.8 (range 6-50)
Donor age (yr) 19.9 6 11.3 (range 3-46)
Recipient height (cm) 145 6 18.3 (range 41-185)
Donor height (cm) 150.2 6 22 (range 39-188)
Recipient sex F49/M54
Donor sex F43/M52
CMV mismatch 59/103
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quently had OB develop. Three of these five have
undergone redo transplantation and the other two
are relisted for transplantation.
The overall timetable of the typical hospital
course after bilateral sequential lung transplantation
for CF is summarized in Table IV. As can be
surmised from the data, patients are generally trans-
ferred out of the intensive care unit approximately
48 hours after being weaned from mechanical ven-
tilation. Patients subsequently required another 2 to
3 weeks of hospitalization for overall rehabilitation
(physical therapy, aggressive nutritional support)
and education, including learning the often compli-
cated medication regimens. Five patients out of the
entire group required postoperative tracheostomy
to assist in weaning from mechanical ventilation.
Bronchial anastomotic complications occurred in
15 of 206 or 7.3% of all anastomoses at risk,
occurring with equal frequency in the pediatric and
adult populations. Stents were required in the treat-
ment of eight of these 15 airway complications.
Complete or near complete bronchial anastomotic
dehiscence occurred three times. One patient with
complete dehiscence was treated with transplant
pneumonectomy and another patient had bilateral,
near complete dehiscence, which, along with B.
cepacia pneumonia and bacteremia, was a contrib-
uting factor in his death. Partial dehiscence occurred
in one anastomosis, and this was treated expectantly
and resolved uneventfully. Stenosis of the airway
anastomosis occurred 11 times. Silicone rubber
stents were placed in eight and dilation alone was all
that was required in three.
Treatment for acute cellular rejection as docu-
mented by transbronchial biopsy and graded by
standard criteria occurred primarily in the first year
after transplantation.10 An average of 1.7 6 1.4
episodes of acute cellular rejection occurred per
patient in the first 6 months after transplantation,
whereas 0.7 6 1.3 episodes occurred per patient for
the remainder of the follow-up period beyond 6
months. OB syndrome as determined by significant
decline in FEV1 generally in conjunction with a
transbronchial biopsy was diagnosed an average of
17.3 6 14.1 months postoperatively (range 2 to 54
months). As demonstrated in Fig. 1, actuarial free-
dom from this entity was 63% and 43% at 2 and 3
years after transplantation, respectively. The inci-
dence of OB after transplantation in patients with
CF is comparable to that seen in our other lung
transplant populations.
The microbial spectrum was relatively typical for
a group of patients with CF in that significant
growth of Pseudomonas species from preoperative
sputum culture was virtually a ubiquitous finding. A
total of three patients with B. cepacia underwent
transplantation. Other organisms obtained on pre-
operative sputum culture included methicillin-resis-
tant Staphylococcus aureus in two patients and My-
cobacterium avium and Mycobacterium cheloneii in
one patient each. Lower respiratory infection re-
quiring treatment with antibiotics most commonly
occurred early after transplantation, with an average
of 1.2 such infections per patient in the first year
after transplantation. Diagnosis of lower respiratory
infection was made by a combination of clinical
picture, chest radiograph, and more than 100,000
colony-forming units/ml on quantitative BAL. The
organism isolated was usually consistent with the
pretransplantation flora. Preoperative airway cul-
ture positive for fungus in low colony counts was
relatively common. In contrast, significant postoper-
ative fungal infection occurred in only 13 of 103
transplantations, and species of fungi cultured in-
cluded Aspergillus fumigatis, Candida parasalopsis,
and Rhizopus. All significant fungal infections were
successfully treated with a combination of intrave-
nous, oral, and aerosolized medications with the
exception of one patient who was found to have
disseminated aspergillosis on autopsy. CMV pneu-
monitis occurring after the initial prophylactic post-
operative course of ganciclovir was relatively com-
mon, taking place in 63 of 103 transplantations.
Although the incidence of donor/recipient CMV
mismatch was similar between adult and pediatric
age groups, CMV pneumonitis tended to be more
common in the former (48% vs 30%, p 5 not
significant). Three patients had postoperative empy-
ema, all of which responded to thoracostomy tube
drainage and appropriate antibiotics.
Pulmonary function rapidly improved after lung
transplantation. Compared with preoperative val-
ues, significant improvement in FEV1 and FVC was
observed at all time intervals up to 2 years after
transplantation (Fig. 2). This is accompanied by a
steady and significant improvement in the 6-minute
walk test results (Table V). The average follow-up
Table IV. Postoperative course (values expressed as
median)
Mechanical ventilation (days) 3 (range 1-47)
Intensive care unit stay (days) 5 (range 1-53)
Hospitalization (days) 20 (range 9-225)
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values of both these parameters includes patients in
whom OB has developed and, thus, tends to under-
estimate the true functional status of those not
affected with this entity. These parameters of func-
tional improvement after transplantation in patients
with CF parallel results obtained from other groups
of patients undergoing pulmonary transplantation
for end-stage lung disease.11
Discussion
Less than 10 years ago, reports surfaced in the
literature that painted a discouraging picture re-
garding heart-lung or bilateral lung transplantation
for patients with CF, with early mortality ranging
from 15% to 35% and an actuarial survival ranging
from 42% to 64% at 1 year.12-14 These early reports
and others15 suggested that infectious complications
were a major obstacle to survival after transplanta-
tion in this group of patients. As it became clear that
the original disease would not recur16 and that the
risk of sepsis in the transplanted lungs was not an
insurmountable problem, bilateral lung transplanta-
tion became the accepted and the most widely
applied surgical therapy for patients with end-stage
lung disease from CF.
Nonetheless, the CF patient population presents
formidable tasks with respect to numerous aspects
of transplantation because, despite end organ fail-
ure being limited to one system, chronic malnutri-
tion affecting wound healing and respiratory muscle
function, pancreatic insufficiency influencing gastro-
intestinal absorption of immunosuppressive medica-
tions, and chronic infection in the paranasal sinuses
all predispose to complications after transplanta-
tion. As worldwide experience has accumulated with
lung transplantation for CF, results have signifi-
cantly improved as documented in the impressive
report of 44 lung transplantations by Egan and
associates,17 in which no operative mortality oc-
curred and the actuarial survival at 1 and 2 years was
85% and 67%, respectively.
Reports have demonstrated that FEV1 and FVC
at time of listing are prognostic indicators in patients
with CF awaiting transplantation.1, 18 The severity of
illness before transplantation in our group of pa-
tients is also reflected both in the number of patients
who had undergone previous surgery or thoracos-
tomy tube/pleurodesis (28%) and in the number
who were on mechanical ventilation (17.5%) preop-
eratively. The report from the Marseille-Montreal
Lung Transplant Program demonstrated an early
mortality of 30% in patients with CF who were
Fig. 1. Actuarial freedom from obliterative bronchiolitis (OB).
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mechanically ventilated preoperatively.19 Aeba and
coworkers20 proposed that length of need for me-
chanical ventilation after transplantation is pro-
longed by use of CPB. This concept is not supported
by the finding that our adult population, in which
bypass was used selectively and in a minority of
patients, had a median duration of mechanical
ventilatory support identical to that in our pediatric
population in which bypass was used routinely.
Infection is the most common cause of early
morbidity and mortality in all lung transplantation
recipients, and on the basis of this study, it is also the
case in patients with CF. Bacteremia or viral, fungal,
or bacterial lower respiratory infection were impor-
tant contributing factors in all cases of early mortal-
ity. Nonetheless, our finding of a relatively low
incidence of postoperative lower respiratory infec-
tions requiring antimicrobial therapy supports the
work of others. The preoperative underlying suppu-
rative process involving the lungs and the persistent
tracheal and sinus reservoirs that exist postopera-
tively do not place the success of the transplantation
at undue risk. A recent study from our institution
demonstrated that CF and non-CF recipients have a
similar median occurrence of their first pulmonary
infections after transplantation.22 Similarly, growth
of fungus from preoperative sputum specimen did
not seem to predispose to significant postoperative
fungal infections, a finding also supported by recent
reports.22 Colonization with panresistant Pseudomo-
nas serves as a relative but not absolute contraindi-
cation to transplantation. Although it has been
suggested that matching CMV status of the do-
nor23, 24 and recipient reduces the incidence of
primary CMV infections after transplantation, we
have not adopted a policy of matching donor and
recipient for CMV status. As previously delineated,
although the incidence of donor/recipient mismatch
or cases of both donor and recipient being positive
were similar between groups, CMV prophylaxis is
used more frequently in the pediatric population
and the need for treatment of CMV disease was
more common in the adult population.
Disruption or stenosis of the bronchial suture line
occurred in 7.3% of bronchial anastomoses at risk in
our series and can generally be managed nonsurgi-
cally. Wrapping of the bronchial anastomosis with
omentum or pericardium to enhance revasculariza-
tion and healing has been performed in the past by
several centers.25 A previous study from our institu-
tion revealed that the use of mattress-type suture
technique (as opposed to simple interrupted or
figure of eight) for the bronchial anastomosis was
associated with increased risk of complications.26
Omental or pericardial wrapping of the bronchial
anastomosis did not confer a decreased risk of such
occurrences and, as a result, is no longer performed.
Localized bronchial anastomotic stenoses have been
managed with good results by a variety of interven-
tions, including rigid bronchoscopic dilatation, hy-
drostatic balloon dilatation, or polymeric silicone
stent placement.
Three-year actuarial survival (Fig. 3) of 56% in
our adult population is consistent with the predicted
3-year survival for adult bilateral lung transplant
recipients in data published by the St. Louis Inter-
national Lung Transplant Registry in January 1997.
In contrast, the 3-year actuarial survival of 73% in
our pediatric population is well above the 50%
3-year survival for all pediatric lung transplant re-
cipients reported to the Registry as of January 1997.
This may be due in part to our willingness to offer
retransplantation as an option when the graft fails.
Specifically, two of three patients with primary graft
failure underwent successful retransplantation and
are still alive. Likewise, two of three patients who
had a clinical course in which decreased immuno-
suppression as therapy for PTLD led to remission of
the PTLD but onset of OB have had successful
retransplantation.
Fig. 2. Pulmonary function pretransplant (PRE-TXP)
and posttransplant.
Table V. Six-minute walk results (feet)
Preoperative 1425 6 436 (n 5 87)
3 Months postoperative 1960 6 404 (n 5 87)
6 Months postoperative 2111 6 345 (n 5 74)
12 Months postoperative 2220 6 335 (n 5 65)
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We are still confronted with the very troublesome
issue of PTLD. The incidence of just more than 17%
in our pediatric population is similar to that re-
ported by Armitage and associates,23 and all but two
of our patients had PTLD develop within the first
year after transplantation. The median time to onset
of this complication in our patients was 4 months
(range 2 to 56 months), and of the two patients in
Fig. 3. A, Four-year actuarial survival for the entire group. B, Three-year actuarial survival by group.
SLCH, Saint Louis Children’s Hospital; BJH, Barnes-Jewish Hospital.
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whom PTLD developed late, one was diagnosed at
autopsy 2 years after transplantation and the other
was diagnosed 56 months after transplantation. Fur-
ther investigation into the role of donor and recip-
ient Epstein-Barr virus status and immunosuppres-
sion strategies are ongoing.
Finally, three of nine patients undergoing retrans-
plantation died before hospital discharge for an
early mortality in this subgroup of patients of 33%.
This outcome is in keeping with previous reports
showing that actuarial survival of adult and pediatric
lung and heart-lung retransplant patients is mark-
edly worse than recipients of initial transplants with
a 1-year survival of less than 40%.27 Living donor
lung transplantation has thus far been considered a
final option when it becomes unlikely, on the basis
of the recipient’s condition and place on the waiting
list, that cadaveric organs will become available to
save the life of the recipient. Eight patients in the
entire group met these criteria, four of whom had
undergone prior transplantation and seven of the
eight (87.5%) are early and midterm survivors.
Bilateral lung transplantation can be performed
with acceptable morbidity and mortality in patients
with CF. Many questions remain unanswered, and
important deterrents exist to long-term survival.
Included in the list of challenges for the future are
means of increasing the donor organ pool by better
donor identification, innovative strategies such as
living donor transplantation and use of non-heart-
beating donors, research into prevention and treat-
ment of OB, achieving a better understanding of the
cause and optimal therapy for PTLD, and develop-
ing new and improved treatments for rejection.
Although more definitive treatments and a true cure
for CF through gene therapy may be on the horizon,
optimizing and advancing our current understand-
ing of lung transplantation currently provides the
only survival opportunity for patients who are inca-
pacitated by the ravages of this disease.
We gratefully acknowledge the hard work, dedication,
and sleepless nights contributed by Saundra Basile, Jenny
Coles, Laura Ochoa, Greg Richardson, Susan Ruble, Kate
Sanders, Pegi Shaner, Debbie Springhart, Donna
Watkins, and Syma Waxman. Without their effort, this
would not have been possible.
R E F E R E N C E S
1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J
Respir Crit Care Med 1996;154:1229-56.
2. Fitzsimmons SC. The changing epidemiology of cystic fibro-
sis. J Pediatr 1992;122:1-8.
3. Noirclerc M, Chuzalette JP, Metras D, et al. Les transplan-
tations bipulmonaires: rapport de la premiere observation
Francaise et commentaires des cinq suivantes. Ann Chir
1989;43:597-600.
4. St. Louis International Lung Transplant Registry—January
1997 Report.
5. Kerem E, Reisman J, Corey M, Canny GJ, Levison H.
Prediction of mortality in patients with cystic fibrosis. N Engl
J Med 1992;326:1187-91.
6. Ciriaco P, Egan TM, Cairns EL, et al. Analysis of cystic
fibrosis referrals for lung transplantation. Chest 1995;107:
1323-7.
7. Sundaresan S, Trachiotis GD, Aoe M, Patterson GA. Donor
lung procurement: assessment and operative technique. Ann
Thorac Surg 1993;56:1409-13.
8. Pasque MK, Cooper JDK, Kaiser LR. Improved technique
for bilateral lung transplantation: rationale and initial expe-
rience. Ann Thorac Surg 1990;49:785-91.
9. Jaquiss RD, Huddleston CB, Spray TL. The use of aprotinin
in pediatric lung transplantation. J Heart Lung Transplant
1995;14:302-7.
l0. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990
working formulation for the classification of pulmonary allo-
graft rejection: lung rejection study group. J Heart Lung
Transplant 1996;15:1-15.
1l. Dromer C, Velly JF, Jougon J, et al. Long-term functional
results after bilateral lung transplantation. Ann Thorac Surg
1993;56:68-73.
12. Frist WH, Fox MD, Campbell PW, et al. Cystic fibrosis
treated with heart-lung transplantation: North American
results. Transplant Proc 1991;23:1205-6.
13. Ramirez JC, Patterson GA, Winton TL, et al. Bilateral lung
transplantation for cystic fibrosis. J Thorac Cardiovasc Surg
1992;103:287-94.
14. Shennib H, Noirclerc M, Ernst P, Metras D, et al. Double-
lung transplantation for cystic fibrosis. Ann Thorac Surg
1992;54:27-32.
15. Griffith BP, Hardestly RL, Armitage JM, et al. A decade of
lung transplantation. Ann Surg 1993;218:310-20.
16. Wood A, Higenbottam T, Jackson M, et al. Airway mucosal
bioelectric potential difference in cystic fibrosis after lung
transplantation. Am Rev Respir Dis 1989;140:1645-9.
17. Egan TM, Detterbeck FC, Mill MR, et al. Improved results
of lung transplantation for patients with cystic fibrosis. J Tho-
rac Cardiovasc Surg 1995;109:224-35.
18. Hayden AM, Robert RC, Kriett JM, et al. Primary diagnosis
predicts prognosis of lung transplant candidates. Transplan-
tation 1993;55:1948-50.
19. Massard G, Shennib H, Metras D, et al. Double-lung trans-
plantation in mechanically ventilated patients with cystic
fibrosis. Ann Thorac Surg 1993;55:1087-92.
20. Aeba R, Griffith BP, Kormos RL, et al. Effect of cardiopul-
monary bypass on early graft dysfunction in clinical lung
transplantation. Ann Thorac Surg 1994;57:715-22.
21. Cohen AH, Sweet S, Mendeloff E, Huddleston CB, Mallory
G. Lower respiratory infections following lung transplanta-
tion in cystic fibrosis [abstract]. Presented at the Tenth
Annual North American CF Conference, October, 1996.
22. Sweet SC, Cohen AH, Mallory GB. Significance of pre-
transplant airway colonization with Aspergillus in pediatric
lung transplant [abstract]. Presented at the Tenth Annual
North American CF Conference, October 1996.
23. Armitage JM, Kurland G, Michaels M, et al. Critical issues in
The Journal of Thoracic and
Cardiovascular Surgery
February 1998
4 1 2 Mendeloff et al.
pediatric lung transplantation. J Thorac Cardiovasc Surg
1995;109:60-5.
24. Bando K, Paradis IL, Komatsu K, et al. Analysis of time-
dependent risks for infection, rejection, and death after
pulmonary transplantation. J Thorac Cardiovasc Surg 1995;
109:49-59.
25. LoCicero J, Massad M, Oba J, Bresticker M. Short-term and
long-term results of experimental wrapping techniques for
bronchial anastomosis. J Thorac Cardiovasc Surg 1992;103:
763-6.
26. Date H, Trulock EP, Arcidi JM, Sundaresan S, Cooper JD,
Patterson GA. Improved airway healing after lung transplan-
tation: an analysis of 348 bronchial anastomoses. J Thorac
Cardiovasc Surg 1995;110:1424-33.
27. Hosenpud JD, Novick FJ, Breen TJ, et al. The Registry of the
International Society for Heart and Lung Transplantation:
Twelfth Official Report–1995. J Heart Lung Transplant 1995;
14:805-15.
Discussion
Dr. Frank C. Detterbeck (Chapel Hill, N.C.). I would
like to congratulate the members of the teams at St. Louis
Children’s Hospital and Barnes Hospital for fine results in
this combined series that we just heard about.
At the University of North Carolina we have done 81
transplantations in patients with CF with a 3-year survival
of 61% and freedom from OB of 52%. So you can see that
our overall results are very much the same, but some
differences exist in the fine points, and I would like you to
comment on three areas.
Your length of intubation was fairly long, almost a
week. What do you think is the cause of that? I wonder if
CPB has something to do with it. In our experience CPB
was related to the length of intubation, and we have tried
to avoid cardiopulmonary bypass for that reason. Even in
patients who are less than 30 kg or 40 kg or patients who
are on a ventilator preoperatively, we have found that we
can usually avoid bypass and only need to resort to bypass
approximately 15% of the time.
I would also like to ask about the nutritional status of
the patients. In your report you implied that this corre-
lated with a protracted hospital course. Do you have any
data that support that? Low body weight is almost univer-
sal in patients with CF. We certainly have used feeding
aggressively as well, but we find that when the feeding is
due not to malabsorption but to increased CO2 produc-
tion, we really cannot have much of an impact by feeding
patients aggressively preoperatively.
Last, I want you to comment on the issue of the
respiratory flora before transplantation, specifically B.
cepacia and panresistant organisms. You have done trans-
plants in three patients with B. cepacia. During the same
period of time we have transplanted almost three times as
many patients with good results. In terms of panresis-
tance, we recently looked at our data and found, to our
surprise, that 40% of our patients had panresistant organ-
isms at the time of transplantation, and yet, surprisingly,
we found no difference in the survival or length of
hospitalization or incidence of pneumonia in the panre-
sistant patients versus the others. Have you looked at this
and do you have any comments about it?
Dr. Hani Shennib (Montreal, Quebec, Canada). I would
like to congratulate the St. Louis group for their outstand-
ing results with transplantation for a very difficult group of
patients, namely, CF patients.
I would like to ask if you could give us an idea why your
results are superior to the results that are produced by the
International Society of Heart and Lung Transplantation.
Is it because you select your patients better? Do you
eliminate patients with B. cepacia?
When you talk about mechanical ventilation, we now
know that mechanical ventilation can have different mo-
dalities. It could be on intubated patients or it could be on
patients who are not intubated on binasal positive airway
pressure or continuous positive airway pressure. How
many of those patients mechanically ventilated are actu-
ally intubated? I would also like to get your opinion as to
how you handle the issue of Epstein-Barr virus serologic
findings that are negative in those patients in view of the
incidence of lymphoproliferative disorders.
Finally, how many of the living related donors in the
transplants you have performed actually were intubated at
the time of transplantation, at least to give us an idea of
when you decide to perform living related transplants? I
guess an issue here is also the question of how many
patients are dying waiting for transplantation of a cadav-
eric donor and whether a process of natural selection for
patients who are arriving to transplantation exists (i.e., are
you actually transplanting better patients and the sicker
patients are dying on the list?).
Dr. Dominique R. Metras (Marseille, France). Since
1988, we have had an experience of 39 transplantations,
including 6 retransplantations done in the CF pediatric
patients from age 5 to 16 years, with a mean age of 11, and
support the authors’ concepts in this subgroup. Bilateral
single-lung transplantation done with the use of CPB is a
safe and reproducible technique with excellent short-term
results. As a matter of fact, we had no mortality in the first
month for primary transplantation and no complication
could be related to the use of CPB, in particular, bleeding
or length of postoperative ventilation. I wish, however, to
ask the author questions related to the CMV complica-
tions and prophylaxis. In our experience half of the
midterm or late deaths were due to either intractable
CMV lung infection or chronic lung dysfunction after cure
of a severe CMV infection despite all protocols of immu-
nosuppression and CMV prophylaxis. We also found a
significant difference in long-term survival in positive
CMV donors, particularly with negative recipients.
My questions to the author are as follows: First, what
was the impact of CMV infection on the early results and
late dysfunction of the lung or OB in your experience?
What prophylaxis protocol would you recommend at
present? And finally, do you try to match donor and
recipient?
Dr. Mendeloff. I thank all of the discussants for their
questions and I will try to answer them in order.
First of all, Dr. Detterbeck, I would like to thank you
for reviewing the manuscript, and, as your results demon-
strate, we continue to be very impressed at the transplan-
tation work that you have previously published and again
now these updated figures.
With respect to length of intubation as stated, I think
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one of the things that explains the average length of
intubation being almost a week is that there were several
outliers that were intubated a long time and that skewed
the average. If you look at the median length of intuba-
tion, it was actually 3 days. With respect to use of CPB, I
know that work had been done by Dr. Aeba, and also data
from your paper several years ago suggesting that CPB
contributed to lengthy intubation. In fact, in our adult
population in which CPB was used selectively and in a
minority of patients, the actual length of intubation was
longer than in the pediatric patients. So we do not have
data to support that that in fact is true, at least for our
population.
With respect to nutritional status and what is written in
the manuscript, we have not done a critical analysis of
nutritional status as a predictor of survival or outcome. All
I would say is that we try to emphasize very aggressive
nutritional support once these people move close to our
transplant center and even before that so as to try to
improve on their cachexia. A nutritionally depleted state
certainly can contribute to respiratory muscle dysfunction
and overall weakness after transplantation.
With respect to resistant flora, as you said, there are
three patients in our entire population that we trans-
planted with B. cepacia, and one of these three died with
B. cepacia infection both in the lungs and bloodstream.
We have not used the presence of B. cepacia as an
absolute contraindication but rather as a relative contra-
indication to transplantation. Microbiologists are starting
to break down the Burkholderia into subspecies, and we
are finding that in most of them we can find some type of
synergistic antibiotic treatment for getting rid of that
organism, and, as a result, it is only used as a relative
contraindication, certainly not absolute. With respect to
other flora cultured preoperatively, multiple patients have
had panresistant Pseudomonas, and we have not used that
as a contraindication to transplantation, nor have we
found it to be a big problem after transplantation.
Dr. Shennib wanted to know how our survival is better
for the pediatric transplant group compared to what is
reported by the Registry, and I think that if you look at
organ survival, actually our results are no better, but if you
look at patient survival, we are saving several patients
from being statistics on our mortality by (1) retransplant-
ing them early on for primary graft failure and (2) taking
several patients who would have died from either PTLD
or OB that developed after decreasing immunosuppres-
sion for PTLD and retransplanted them, and they are
survivors. So those are people who would have otherwise
died who have survived. So I do not think we are picking
better candidates. It is just a matter of using retransplan-
tation for getting a better long-term survivorship.
With respect to mechanical ventilation, the data repre-
sented here are actual days on mechanical ventilation on
an assist mode. So it would not include people on binasal
positive airway pressure or CPAP.
With respect to Epstein-Barr virus and the lymphopro-
liferative disease, as is apparent from our study and
several other studies, including data produced by the
Pittsburgh group, posttransplantation lymphoproliferative
disease is clearly an important problem and is associated
with Epstein-Barr virus activation. We are currently scru-
tinizing the donor and recipient Epstein-Barr virus status
for the entire population, and in addition we are investi-
gating Epstein-Barr virus polymerase chain reactions and
trying to figure out the use of those as far as predicting
who might have this disease develop and how people are
responding to treatment of this disease.
Four of the nine living donor transplants were intubated
before undergoing their procedure. And finally, Dr. Me-
tras, in response to your question regarding CMV com-
plications, it has been pretty much a uniform finding in all
of the lung transplant data, including Dr. Detterbeck’s
paper. They had almost a 60% involvement with CMV
complications. We use ganciclovir prophylaxis when either
donor or recipient is positive for IgG in the pediatric
population, and in the adult population we are using
ganciclovir prophylaxis when donors are CMV positive
but recipients are CMV negative. It appears that a little
bit more aggressive ganciclovir prophylaxis early postop-
eratively has resulted in a lower incidence of CMV in the
pediatric population.
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